Hiroshima, 734-8551
Japan
Hiroshima University - Hiroshima University Hospital
locally advanced, Non-small cell lung cancer (NSCLC), older patients, chemoradiotherapy, daily low-dose carboplatin, carboplatin plus nab-paclitaxel
Lung cancer, MET, acquired resistance, cabozantinib, clinical trial
Non-small cell lung cancer, Performance status 2, Immune checkpoint inhibitors, Real-world evidence, First-line therapy